Gene study could unlock diabetes mystery

NCT ID NCT06972407

Not yet recruiting Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how a common genetic change (the T allele at rs7903146) affects the pancreas's own production of GLP-1, a hormone that helps control blood sugar. Researchers will give 80 healthy adults a drug that blocks GLP-1 receptors to see how their insulin and glucagon levels change. The goal is to understand why this gene variant raises the risk of type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Exendin 9-39 (a GLP-1 receptor blocker)
What this could lead to: If successful, this could clarify how a common gene variant raises diabetes risk, potentially pointing toward new prevention or treatment strategies.
What could go wrong: This is an early-phase, small study (80 people) focused on understanding biology, not testing a treatment. It may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETIC PREDISPOSITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited disease susceptibility type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETIC PREDISPOSITION TYPE2DIABETES

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.